|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Lung Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Carcinoma, Non-Small-Cell Lung | |||||
| Lung Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Carcinoma | |||||
| Lung Diseases | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms by Site | |||||
| Neoplasms, Glandular and Epithelial | |||||
| Respiratory Tract Diseases | |||||
| Respiratory Tract Neoplasms | |||||
| Thoracic Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| carboxyamidotriazole | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Carboxyamido-triazole | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Calcium Channel Blockers | |||||
| Cardiovascular Agents | |||||
| Membrane Transport Modulators | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| North Central Cancer Treatment Group | |||||
| National Cancer Institute (NCI) | |||||